These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

521 related articles for article (PubMed ID: 28395559)

  • 1. Management of myelofibrosis: JAK inhibition and beyond.
    Stahl M; Zeidan AM
    Expert Rev Hematol; 2017 May; 10(5):459-477. PubMed ID: 28395559
    [TBL] [Abstract][Full Text] [Related]  

  • 2. How many JAK inhibitors in myelofibrosis?
    Ferreira BV; Harrison C
    Best Pract Res Clin Haematol; 2014 Jun; 27(2):187-95. PubMed ID: 25189729
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Myelofibrosis: an update on drug therapy in 2016.
    Bose P; Verstovsek S
    Expert Opin Pharmacother; 2016 Dec; 17(18):2375-2389. PubMed ID: 27774820
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clarifying the use of ruxolitinib in patients with myelofibrosis.
    Kremyanskaya M; Atallah EL; Hoffman R; Mascarenhas JO
    Oncology (Williston Park); 2013 Jul; 27(7):706-14. PubMed ID: 23977767
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ruxolitinib, an oral JAK1 and JAK2 inhibitor, in myelofibrosis.
    Vaddi K; Sarlis NJ; Gupta V
    Expert Opin Pharmacother; 2012 Nov; 13(16):2397-407. PubMed ID: 23051187
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of ruxolitinib for myelofibrosis.
    Santos FP; Verstovsek S
    Expert Opin Pharmacother; 2014 Jul; 15(10):1465-73. PubMed ID: 24856675
    [TBL] [Abstract][Full Text] [Related]  

  • 7. JAK2 inhibitors for myeloproliferative neoplasms: what is next?
    Bose P; Verstovsek S
    Blood; 2017 Jul; 130(2):115-125. PubMed ID: 28500170
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical efficacy and safety of ruxolitinib in the management of myelofibrosis: A single institution experience in Taiwan.
    Chen YY; Huang CE; Lee KD; Chen CC
    Hematology; 2016 Jan; 21(1):3-9. PubMed ID: 26214121
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Should we be treating lower risk myelofibrosis patients with a JAK2 inhibitor?
    Lancman G; Mascarenhas J
    Expert Rev Hematol; 2017 Jan; 10(1):23-28. PubMed ID: 27882812
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overcoming treatment challenges in myelofibrosis and polycythemia vera: the role of ruxolitinib.
    Bryan JC; Verstovsek S
    Cancer Chemother Pharmacol; 2016 Jun; 77(6):1125-42. PubMed ID: 27017614
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of myelofibrosis after ruxolitinib failure.
    Harrison CN; Schaap N; Mesa RA
    Ann Hematol; 2020 Jun; 99(6):1177-1191. PubMed ID: 32198525
    [TBL] [Abstract][Full Text] [Related]  

  • 12. How I treat myelofibrosis.
    Cervantes F
    Blood; 2014 Oct; 124(17):2635-42. PubMed ID: 25232060
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New Concepts of Treatment for Patients with Myelofibrosis.
    Bose P; Alfayez M; Verstovsek S
    Curr Treat Options Oncol; 2019 Jan; 20(1):5. PubMed ID: 30675650
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Investigational Janus kinase inhibitors in development for myelofibrosis.
    Bose P; Abou Zahr A; Verstovsek S
    Expert Opin Investig Drugs; 2017 Jun; 26(6):723-734. PubMed ID: 28441920
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Myelofibrosis: an update on current pharmacotherapy and future directions.
    Cervantes F; Martinez-Trillos A
    Expert Opin Pharmacother; 2013 May; 14(7):873-84. PubMed ID: 23514013
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Momelotinib versus Continued Ruxolitinib or Best Available Therapy in JAK Inhibitor-Experienced Patients with Myelofibrosis and Anemia: Subgroup Analysis of SIMPLIFY-2.
    Harrison CN; Vannucchi AM; Recher C; Passamonti F; Gerds AT; Hernandez-Boluda JC; Yacoub A; Sirhan S; Ellis C; Patel B; Strouse B; Platzbecker U
    Adv Ther; 2024 Sep; 41(9):3722-3735. PubMed ID: 38990433
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of long-term ruxolitinib treatment on JAK2p.V617F allele burden in patients with myelofibrosis.
    Deininger M; Radich J; Burn TC; Huber R; Paranagama D; Verstovsek S
    Blood; 2015 Sep; 126(13):1551-4. PubMed ID: 26228487
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Primary myelofibrosis: 2023 update on diagnosis, risk-stratification, and management.
    Tefferi A
    Am J Hematol; 2023 May; 98(5):801-821. PubMed ID: 36680511
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ruxolitinib.
    Becker H; Engelhardt M; von Bubnoff N; Wäsch R
    Recent Results Cancer Res; 2014; 201():249-57. PubMed ID: 24756798
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FRACTION: protocol of a phase II study of Fedratinib and Nivolumab combination in patients with myelofibrosis and resistance or suboptimal response to JAK-inhibitor treatment of the German MPN study group (GSG-MPN).
    Isfort S; von Bubnoff N; Al-Ali HK; Becker H; Götze T; le Coutre P; Griesshammer M; Moskwa C; Wohn L; Riedel J; Palandri F; Manz K; Hochhaus A; Döhner K; Heidel FH
    Ann Hematol; 2024 Aug; 103(8):2775-2785. PubMed ID: 38967662
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.